Visualizing the dynamic of adoptively transferred T cells during the rejection of large established tumors

European Journal of Immunology

Volumn 41, Issue 11, 2011, Pages 3187-3197

  Charo, Jehad ^a   Perez, Cynthia ^a   Buschow, Christian ^b   Jukica, Ana ^a   Czeh, Melinda ^b   Blankenstein, Thomas ^a,b  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Adoptive transfer; CD8 + T lymphocytes; Immunologic memory; In vivo imaging; Transgenic mice

Indexed keywords

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLUMINESCENCE; CELL EXPANSION; CELL POPULATION; CELL PROLIFERATION; CELL SURVIVAL; CELL THERAPY; CONTROLLED STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR; TUMOR REJECTION;

ADOPTIVE TRANSFER; ANIMALS; CELL SEPARATION; CELL TRANSPLANTATION; CHEMOTAXIS, LEUKOCYTE; FEMALE; FLOW CYTOMETRY; IMMUNOTHERAPY, ADOPTIVE; LUCIFERASES, RENILLA; LUMINESCENT MEASUREMENTS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL; T-LYMPHOCYTES;

EID: 80054950816     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201141452     Document Type: Article

References (46)

1. Berger, C., Turtle, C. J., Jensen, M. C. and Riddell, S. R., Adoptive transfer of virus-specific and tumor-specific T cell immunity. Curr. Opin. Immunol. 2009. 21: 224-232.
2. Offringa, R., Antigen choice in adoptive T-cell therapy of cancer. Curr. Opin. Immunol. 2009. 21: 190-199.
3. Rosenberg, S. A. and Dudley, M. E., Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr. Opin. Immunol. 2009. 21: 233-240.
4. Charo, J., Finkelstein, S. E., Grewal, N., Restifo, N. P., Robbins, P. F. and Rosenberg, S. A., Bcl-2 overexpression enhances tumor-specific T-cell survival. Cancer Res. 2005. 65: 2001-2008.
5. Leen, A. M., Rooney, C. M. and Foster, A. E., Improving T cell therapy for cancer. Annu. Rev. Immunol. 2007. 25: 243-265.
6. Pockaj, B. A., Sherry, R. M., Wei, J. P., Yannelli, J. R., Carter, C. S., Leitman, S. F., Carasquillo, J. A. et al., Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response. Cancer 1994. 73: 1731-1737.
7. Rosenberg, S. A., Progress in human tumour immunology and immunotherapy. Nature 2001. 411: 380-384.
8. Massoud, T. F. and Gambhir, S. S., Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev. 2003. 17: 545-580.
9. Willmann, J. K., van Bruggen, N., Dinkelborg, L. M. and Gambhir, S. S., Molecular imaging in drug development. Nat. Rev. Drug Discov. 2008. 7: 591-607.
10. Ray, P., Wu, A. M. and Gambhir, S. S., Optical bioluminescence and positron emission tomography imaging of a novel fusion reporter gene in tumor xenografts of living mice. Cancer Res. 2003. 63: 1160-1165.
11. Contag, C. H., In vivo pathology: seeing with molecular specificity and cellular resolution in the living body. Annu. Rev. Pathol. 2007. 2: 277-305.
12. Edinger, M., Cao, Y. A., Hornig, Y. S., Jenkins, D. E., Verneris, M. R., Bachmann, M. H., Negrin, R. S. et al., Advancing animal models of neoplasia through in vivo bioluminescence imaging. Eur J Cancer 2002. 38: 2128-2136.
13. Gattinoni, L., Powell, D. J., Jr., Rosenberg, S. A. and Restifo, N. P., Adoptive immunotherapy for cancer: building on success. Nat. Rev. Immunol. 2006. 6: 383-393.
14. + memory stem cells. Nat. Med. 2009. 15: 808-813.
15. Kast, W. M., Offringa, R., Peters, P. J., Voordouw, A. C., Meloen, R. H., van der Eb, A. J. and Melief, C. J., Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes. Cell 1989. 59: 603-614.
16. Spiotto, M. T., Rowley, D. A. and Schreiber, H., Bystander elimination of antigen loss variants in established tumors. Nat. Med. 2004. 10: 294-298.
17. Zhang, B., Rowley, D. A. and Schreiber, H., Tumor Stroma and the Antitumor Immune Response. In: Gabrilovich, D. I. and Hurwitz, A. A. (Eds.), Tumor-induced Immune Suppression: Mechanisms and Therapeutic Reversal. Springer, New York, NY 2008, pp. 281-294.
18. +T cells. J. Exp. Med. 2003. 198: 569-580.
19. +T cells mediate superior antitumor immunity. Proc. Natl. Acad. Sci. USA 2009. 106: 17469-17474.
20. Greenberg, P. D., Kern, D. E. and Cheever, M. A., Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+, 2- T cells. Tumor eradication does not require participation of cytotoxic T cells. J. Exp. Med. 1985. 161: 1122-1134.
21. Ibe, S., Qin, Z., Schuler, T., Preiss, S. and Blankenstein, T., Tumor rejection by disturbing tumor stroma cell interactions. J. Exp. Med. 2001. 194: 1549-1559.
22. Lake, R. A. and Robinson, B. W., Immunotherapy and chemotherapy - a practical partnership. Nat. Rev. Cancer 2005. 5: 397-405.
23. North, R. J., Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J. Exp. Med. 1982. 155: 1063-1074.
24. Rosenberg, S. A., Spiess, P. and Lafreniere, R., A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986. 233: 1318-1321.
25. Schreiber, K., Rowley, D. A., Riethmuller, G. and Schreiber, H., Cancer immunotherapy and preclinical studies: why we are not wasting our time with animal experiments. Hematol. Oncol. Clin. North Am. 2006. 20: 567-584.
26. Yee, C., Riddell, S. R. and Greenberg, P. D., In vivo tracking of tumor-specific T cells. Curr. Opin. Immunol. 2001. 13: 141-146.
27. Rabinovich, B. A., Ye, Y., Etto, T., Chen, J. Q., Levitsky, H. I., Overwijk, W. W., Cooper, L. J. et al., Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer. Proc. Natl. Acad. Sci. USA 2008. 105: 14342-14346.
28. Santos, E. B., Yeh, R., Lee, J., Nikhamin, Y., Punzalan, B., Punzalan, B., La Perle, K. et al., Sensitive in vivo imaging of T cells using a membrane-bound Gaussia princeps luciferase. Nat. Med. 2009. 15: 338-344.
29. +T cells. J. Clin. Invest. 2005. 115: 1616-1626.
30. Buschow, C., Charo, J., Anders, K., Loddenkemper, C., Jukica, A., Alsamah, W., Perez, C. et al., In vivo imaging of an inducible oncogenic tumor antigen visualizes tumor progression and predicts CTL tolerance. J. Immunol. 2010. 184: 2930-2938.
31. Kruschinski, A., Moosmann, A., Poschke, I., Norell, H., Chmielewski, M., Seliger, B., Kiessling, R. et al., Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas. Proc. Natl. Acad. Sci. USA 2008. 105: 17481-17486.
32. Bhaumik, S. and Gambhir, S. S., Optical imaging of Renilla luciferase reporter gene expression in living mice. Proc. Natl. Acad. Sci. USA 2002. 99: 377-382.
33. Meunier, M. C., Baron, C. and Perreault, C., Two host factors regulate persistence of H7-specific T cells injected in tumor-bearing mice. PLoS One 2009. 4: e4116.
34. +T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction. J. Immunol. 2004. 173: 7209-7216.
35. Schoenberger, S. P. and Crotty, S., Immunologic Memory. In: Paul, W. E. (Ed.), Fundamental Immunology, 6th Edn, Wolters Kluwer/Lippincott Williams & Wilkins, Philadelphia 2008, pp. 862-897.
36. Lefrancois, L. and Obar, J. J., Once a killer, always a killer: from cytotoxic T cell to memory cell. Immunol. Rev. 2010. 235: 206-218.
37. +T cells during an acute virus infection. Immunity 1998. 8: 167-175.
38. +T cells exceeds that of an aggressively growing mouse tumor. Cancer Res. 2006. 66: 1132-1138.
39. Kircher, M. F., Allport, J. R., Graves, E. E., Love, V., Josephson, L., Lichtman, A. H. and Weissleder, R., In vivo high resolution three-dimensional imaging of antigen-specific cytotoxic T-lymphocyte trafficking to tumors. Cancer Res. 2003. 63: 6838-6846.
40. +T cells. J. Exp. Med. 2005. 202: 907-912.
41. Willimsky, G. and Blankenstein, T., Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 2005. 437: 141-146.
42. Zheng, B., Vogel, H., Donehower, L. A. and Bradley, A., Visual genotyping of a coat color tagged p53 mutant mouse line. Cancer Biol. Ther. 2002. 1: 433-435.
43. Gladow, M., Uckert, W. and Blankenstein, T., Dual T cell receptor T cells with two defined specificities mediate tumor suppression via both receptors. Eur. J. Immunol. 2004. 34: 1882-1891.
44. Hogquist, K. A., Jameson, S. C., Heath, W. R., Howard, J. L., Bevan, M. J. and Carbone, F. R., T cell receptor antagonist peptides induce positive selection. Cell 1994. 76: 17-27.
45. Mombaerts, P., Iacomini, J., Johnson, R. S., Herrup, K., Tonegawa, S. and Papaioannou, V. E., RAG-1-deficient mice have no mature B and T lymphocytes. Cell 1992. 68: 869-877.
46. Charo, J., Ciupitu, A. M., Le Chevalier De Preville, A., Trivedi, P., Klein, G., Hinkula, J. and Kiessling, R., A long-term memory obtained by genetic immunization results in full protection from a mammary adenocarcinoma expressing an EBV gene. J. Immunol. 1999. 163: 5913-5919.